secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0000950170-25-079749
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q1 net loss $17.4M; cash jumps to $9.9M on $15M financing and grants
--------------------------------------------------------------------------------

- Cash balance $9.9M at Mar 31, 2025 vs $0.1M at Dec 31, 2024; raised $15M private placement and $2M grant advance.
- Net loss $17.4M ($1.19/share) vs $3.3M ($0.75/share) in Q1 2024; operating loss $3.5M vs $3.3M.
- Completed ReSPECT-LM Phase 1 dose trial; FDA Orphan Drug Designation for REYOBIQ for leptomeningeal metastases in lung cancer.
- Published Phase 1 REYOBIQ data in Nature Communications: >100 Gy dose group median OS 17 months, double standard of care.
- Added board member Kyle Guse; management hires: Dr. Rosol (CDO), Bradley (CNSide President), Stein (Medical Director).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017025079749/0000950170-25-079749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017025079749/pstv-20250530.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-079749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer